Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of Synthetic alpha interferon (Alfacyte) in COVID-19 infections

Next Previous
X
Search
Trial Profile

A clinical trial of Synthetic alpha interferon (Alfacyte) in COVID-19 infections

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 19 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Synthetic alpha interferon-ILC Therapeutics (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions

    • Most Recent Events

    • 13 May 2021 According to an ILC Therapeutics media release, company is preparing Alfacyte to complete the IND application. The company has engaged 3P Bio SA, a leading biologics production service company based in Spain, for the manufacture of Alfacyte as well as UK-based contract research organisation TCRS for clinical trials which are being planned for early 2022.
    • 10 Dec 2020 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top